CH Biotech Ser (08037) announced that its indirectly non-wholly owned subsidiary, Shanghai Longyao Biotechnology Co., Ltd., showcased the phase I clinical study results of LY007, a new CD20 autologous chimeric antigen receptor T-cell therapy product, for patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (B-NHL) at the American Society of Clinical Oncology (ASCO) Annual Meeting in 2024 in the form of a poster presentation.
It is reported that large B-cell lymphoma (LBCL) is a common subtype of B-cell non-Hodgkin's lymphoma. Most patients can be cured by standard chemotherapy regimens. However, about 40% of patients still face the difficulty of relapse and refractory after first-line treatment. The phase I study was aimed at evaluating the safety and tolerability of LY007 cell injection in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. The phase I study showed that LY007 cell injection had good tolerability at dose levels up to 5.0 x 106 cells/kg and displayed a good dose-response relationship in the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma. It is expected that LY007 cell injection will provide a new treatment option for patients with LBCL.
As of December 25, 2023, nine patients had received three doses of LY007 cell injection therapy, with a median follow-up of 5.09 months (range 0.92 to 18.10 months). Eight out of nine patients (89%) had extranodal involvement, and seven out of nine patients (78%) had an international prognostic index (IPI) score of ≥2. Four out of nine patients (44%) had a maximum tumor length of ≥5 cm, and two patients had a maximum tumor length >8 cm.